SCHEMBL13636115

SCHEMBL13636115

CC(C)(C)OC(=O)Nc1cc(Oc2ccc([N+](=O)[O-])nc2)ccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 3/20 0.47
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39
THRB P10828 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TEK Q02763 1/20 0.38
KDR P35968 5/20 0.38
FLT1 P17948 1/20 0.38
LMNA P02545 1/20 0.37
CDK8 P49336 2/20 0.36
CYP17A1 P05093 1/20 0.36
SCN9A Q15858 2/20 0.36
S1PR3 Q99500 1/20 0.36
RIPK1 Q13546 1/20 0.36
RIPK3 Q9Y572 1/20 0.36
RORC P51449 1/20 0.35
MEN1 O00255 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13636107 0.88 ALDH1A1 (0.38) BRAFALDH1A1GAAHTTLMNA
SCHEMBL13636122 0.88 PDK1 (0.39) BRAFCDK8MEN1KMT2APRMT1
SCHEMBL4283775 0.85 LMNA (0.40) ALDH1A1HTTL3MBTL1TEKKDR
SCHEMBL4283781 0.85 LMNA (0.40) ALDH1A1HTTL3MBTL1TEKKDR
SCHEMBL13636118 0.83 CDK8 (0.53) BRAFCDK8
SCHEMBL29996709 0.82 PRMT1 (0.47) ALDH1A1LMNACYP17A1MEN1RAB9A
SCHEMBL1478008 0.82 PRMT1 (0.47) ALDH1A1LMNACYP17A1MEN1RAB9A
SCHEMBL4732688 0.82 CDK8 (0.46) CDK8MEN1KMT2A
SCHEMBL29996697 0.82 CDK8 (0.46) CDK8MEN1KMT2A
SCHEMBL13981854 0.81 BRAF (0.47) BRAFTEKKDRFLT1CDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304557-B2 Fused heterocycle derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-06 US disclosed
US-8304557-B2 Fused heterocycle derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-06 US disclosed
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163488-A1 FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF NOX3, NOX5, ZYX BRAF 1364/4885ALDH1A1 2812/4885GAA 4732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.